PMID- 31541071
OWN - NLM
STAT- MEDLINE
DCOM- 20200203
LR  - 20200203
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 20
DP  - 2019 Sep 21
TI  - A Case of Rituximab-Induced Acute Thrombocytopenia in a Patient with Splenic 
      Marginal Zone Lymphoma and Chronic Hepatitis C Virus Infection.
PG  - 1394-1397
LID - 10.12659/AJCR.917644 [doi]
AB  - BACKGROUND Rituximab is a chimeric monoclonal antibody to CD20 that is used to 
      treat vasculitis, B-cell lymphoproliferative disorders, and B-cell non-Hodgkin 
      lymphoma (NHL). A report is presented of a case of rituximab-induced acute 
      thrombocytopenia (RIAT) in a woman with splenic marginal zone lymphoma (SMZL) and 
      chronic hepatitis C virus (HCV) infection. CASE REPORT A 46-year-old woman with 
      SMZL complicated by chronic HCV infection presented with worsening B symptoms of 
      fever, night sweats, and loss of weight. The patient had a history of 
      recreational drug use. Intravenous treatment with rituximab (dose, 375 mg/m(2)) 
      commenced with close monitoring in hospital. On the following day, the complete 
      blood count (CBC) showed that her platelet count had dropped from her admission 
      level of 167,000/mul to 7,000/mul, with no change in hemoglobin or white blood cell 
      (WBC) levels. A diagnosis of RIAT was made. The patient was managed 
      conservatively and monitored for the development of potential clinical 
      complications. CONCLUSIONS RIAT is a rare complication of treatment with 
      rituximab and may be poorly recognized. Further studies are needed to determine 
      the incidence and causes of thrombocytopenia in patients treated with rituximab 
      and the possible association with chronic viral infections, including HCV.
FAU - Qureini, Aref
AU  - Qureini A
AD  - Department of Internal Medicine, University of Missouri School of Medicine, 
      Kansas City, MO, USA.
FAU - Asif, Samia
AU  - Asif S
AD  - Department of Internal Medicine, University of Missouri School of Medicine, 
      Kansas City, MO, USA.
FAU - Harry, Stephanie
AU  - Harry S
AD  - Department of Hematology and Oncology, University of Missouri School of Medicine, 
      Kansas City, MO, USA.
FAU - Madhusudhana, Sheshadri
AU  - Madhusudhana S
AD  - Department of Hematology and Oncology, University of Missouri School of Medicine, 
      Kansas City, MO, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20190921
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*adverse effects
MH  - Female
MH  - Hepatitis C, Chronic/complications
MH  - Humans
MH  - Lymphoma, B-Cell, Marginal Zone/drug therapy
MH  - Middle Aged
MH  - Rituximab/*adverse effects
MH  - Splenic Neoplasms/drug therapy
MH  - Thrombocytopenia/*chemically induced
PMC - PMC6767946
COIS- Conflict of interest: None declared Conflict of interest None.
EDAT- 2019/09/22 06:00
MHDA- 2020/02/06 06:00
PMCR- 2019/09/21
CRDT- 2019/09/22 06:00
PHST- 2019/09/22 06:00 [entrez]
PHST- 2019/09/22 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PHST- 2019/09/21 00:00 [pmc-release]
AID - 917644 [pii]
AID - 10.12659/AJCR.917644 [doi]
PST - epublish
SO  - Am J Case Rep. 2019 Sep 21;20:1394-1397. doi: 10.12659/AJCR.917644.